Rosetta Capital IV

Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.

Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.

Carrick Therapeutics, Ltd., established in 2015 and headquartered in Dublin, Ireland, focuses on developing innovative cancer therapeutics aimed at transforming cancer treatment. The company targets molecular pathways associated with aggressive and resistant forms of cancer, employing advanced mechanisms to improve treatment outcomes. By enabling the detection of predictive biomarkers, Carrick Therapeutics facilitates the initiation of targeted therapies at early stages, ultimately striving to enhance the lives of cancer patients.

Asarina Pharma AB is a Swedish biotechnology company dedicated to developing innovative therapies for premenstrual dysphoric disorder (PMDD) and other menstrually related conditions. The company is advancing Sepranolone (UC1010), a treatment specifically targeting PMDD, and is also working on a second-generation oral compound currently in preclinical development for the same disorder. Asarina's research is grounded in over 40 years of study into allopregnanolone-related neurological disorders, and it aims to create a new family of compounds known as GAMSA (GABA-A Modulating Steroid Antagonists). These compounds are intended to provide effective and safe treatment options for a range of neuroendocrinological conditions that remain largely untreated.

Modus Therapeutics AB is a clinical-stage drug development company based in Stockholm, Sweden, focused on creating pharmaceutical therapies. Founded in 2011, the company is developing sevuparin, a novel drug aimed at treating sickle cell disease, a painful inherited blood disorder that affects millions worldwide. In addition to its primary focus on sickle cell disease, Modus Therapeutics is also exploring the potential of sevuparin for treating conditions associated with severe systemic inflammation, such as sepsis, endotoxemia, and severe malaria, as well as anemia related to chronic inflammation, including kidney diseases. Through its innovative approach, Modus Therapeutics aims to improve patient outcomes and reduce healthcare costs associated with these disorders.

Dilafor AB is a Swedish drug development company established in 2003, based in Solna. It focuses on creating pharmaceutical products specifically for obstetric applications. The company is known for its development of Tafoxiparin, which serves as an adjuvant therapy to enhance cervical ripening and myometrial contractility. Dilafor aims to address the challenges associated with slow progress of labor, both during induced and spontaneous labor. The company investigates the pharmacological properties of low anticoagulant heparin derivatives, contributing to improved outcomes for mothers and infants by reducing risks related to protracted labor, such as severe fetal asphyxia and postpartum hemorrhage. Through its innovative approaches, Dilafor seeks to promote healthier lives for mothers, children, and families.

NovImmmune is committed to innovation by discovering and developing therapeutic monoclonal antibodies (mAbs) to treat patients suffering from immune-related disorders.

Asarina Pharma AB is a Swedish biotechnology company dedicated to developing innovative therapies for premenstrual dysphoric disorder (PMDD) and other menstrually related conditions. The company is advancing Sepranolone (UC1010), a treatment specifically targeting PMDD, and is also working on a second-generation oral compound currently in preclinical development for the same disorder. Asarina's research is grounded in over 40 years of study into allopregnanolone-related neurological disorders, and it aims to create a new family of compounds known as GAMSA (GABA-A Modulating Steroid Antagonists). These compounds are intended to provide effective and safe treatment options for a range of neuroendocrinological conditions that remain largely untreated.

Biosergen AS is a biotechnology company focused on the development of innovative antifungal drugs, leveraging advanced biopharmaceutical research. Operating from its laboratory facilities in Trondheim, Norway, and other locations globally, Biosergen is working on various pipeline products, including S44HP, an antibiotic exhibiting enhanced potency against a range of fungal pathogens compared to traditional nystatin. The company is also developing BSG005, a promising antifungal agent that shows significant safety and efficacy benefits over existing treatments. Additionally, Biosergen explores nystatin analogues through genetic manipulation of the nystatin biosynthetic pathway, aiming to improve therapeutic outcomes in the treatment of fungal infections.

Aprea is a biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development. Aprea Therapeutics was established in 2003 in Stockholms Lan, Sweden by Klas Wiman and Galina Selivanova.

EyeSense AG specializes in the development of ophthalmic diagnostic systems aimed at improving glucose testing for diabetic patients. The company focuses on creating innovative, pain-free blood glucose monitoring devices that facilitate better diabetes management. By utilizing advanced fiber optic sensors, EyeSense AG's technology enables continuous blood sugar measurement, thereby enhancing the therapy and care available to individuals with diabetes.